MX2016010345A - Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas. - Google Patents
Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas.Info
- Publication number
- MX2016010345A MX2016010345A MX2016010345A MX2016010345A MX2016010345A MX 2016010345 A MX2016010345 A MX 2016010345A MX 2016010345 A MX2016010345 A MX 2016010345A MX 2016010345 A MX2016010345 A MX 2016010345A MX 2016010345 A MX2016010345 A MX 2016010345A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- pathological
- immune cells
- antigen present
- immunotherapy
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 1
- 102000008682 Argonaute Proteins Human genes 0.000 abstract 1
- 108010088141 Argonaute Proteins Proteins 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 108091033409 CRISPR Proteins 0.000 abstract 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 101710152694 Cysteine synthase 2 Proteins 0.000 abstract 1
- 108010042407 Endonucleases Proteins 0.000 abstract 1
- 102000004533 Endonucleases Human genes 0.000 abstract 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 102100029873 Small muscular protein Human genes 0.000 abstract 1
- 238000010459 TALEN Methods 0.000 abstract 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Métodos de desarrollo de células inmune diseñados genéticamente para inmunoterapia, las cuales se encuentran dotadas con Receptores de Antígenos Quiméricos que dirigen un marcador de antígeno que es común tanto para las células patológicas y las células inmunes (ejemplo: CD38, CS1 o CD70) por el hecho de que los genes que dosifican los marcadores están inactivos en las células inmune por una endonucleasa de corte poco frecuente tal como TALEN, Cas9 o argonauta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201470076 | 2014-02-14 | ||
PCT/EP2015/053162 WO2015121454A1 (en) | 2014-02-14 | 2015-02-13 | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010345A true MX2016010345A (es) | 2017-01-23 |
Family
ID=50114255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010345A MX2016010345A (es) | 2014-02-14 | 2015-02-13 | Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas. |
Country Status (19)
Country | Link |
---|---|
US (3) | US10836998B2 (es) |
EP (2) | EP3505623A1 (es) |
JP (1) | JP6673838B2 (es) |
KR (1) | KR102157924B1 (es) |
CN (1) | CN106029875A (es) |
AU (1) | AU2015216875B2 (es) |
BR (1) | BR112016017806B1 (es) |
CA (1) | CA2937711C (es) |
DK (1) | DK3105317T3 (es) |
ES (1) | ES2711498T3 (es) |
HU (1) | HUE041497T2 (es) |
IL (1) | IL246645B (es) |
MX (1) | MX2016010345A (es) |
NO (1) | NO20161276A1 (es) |
PL (1) | PL3105317T3 (es) |
PT (1) | PT3105317T (es) |
RU (1) | RU2714258C2 (es) |
TR (1) | TR201819571T4 (es) |
WO (1) | WO2015121454A1 (es) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
CA2931267C (en) * | 2013-11-22 | 2023-08-15 | Cellectis | A method of engineering allogenic and drug resistant t-cells for immunotherapy |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
MX2017000646A (es) * | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
US9777061B2 (en) * | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
RU2727451C2 (ru) | 2014-12-05 | 2020-07-21 | Сити Оф Хоуп | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 |
EP3234120A4 (en) | 2014-12-15 | 2018-05-16 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
RU2732925C2 (ru) | 2015-01-26 | 2020-09-24 | Селлектис | МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК |
EP3062105A1 (en) * | 2015-02-26 | 2016-08-31 | Université de Bretagne Occidentale (U.B.O.) | Processes for the diagnosis, prognosis and monitoring of the progression of Chronic Lymphoid Leukaemia (CLL) and/or of Systemic Lupus Erythematosus (SLE) using membrane STIM 1 |
WO2016138491A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
EP3268388A1 (en) | 2015-03-11 | 2018-01-17 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
AU2016264323B2 (en) | 2015-05-18 | 2021-02-18 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
AU2016283102B2 (en) | 2015-06-25 | 2021-03-11 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
JP7409773B2 (ja) | 2015-07-31 | 2024-01-09 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 改変された細胞および治療の方法 |
AU2016318230B2 (en) * | 2015-09-11 | 2020-05-21 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
US10928392B2 (en) | 2015-09-25 | 2021-02-23 | Abvitro Llc | High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences |
EP3756682B8 (en) | 2015-10-05 | 2022-04-27 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
EP3362472B1 (en) * | 2015-10-16 | 2023-08-30 | The Trustees of Columbia University in the City of New York | Compositions and methods for inhibition of lineage specific antigens |
IL310721A (en) | 2015-10-23 | 2024-04-01 | President And Fellows Of Harvard College | Nucleobase editors and their uses |
SG11201803678SA (en) | 2015-11-03 | 2018-05-30 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
EP3377076A4 (en) * | 2015-11-19 | 2019-07-31 | Bloodcenter Research Foundation | METHOD FOR PRODUCING BI-SPECIFIC T CELLS FOR USE IN ANTICANCER IMMUNOTHERAPY |
CN105368859B (zh) * | 2015-11-25 | 2019-10-18 | 王任直 | 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用 |
JP7362250B2 (ja) * | 2016-03-04 | 2023-10-17 | モルフォシス・アーゲー | 多発性骨髄腫におけるmタンパク質反応の臨床評価 |
WO2017177175A1 (en) * | 2016-04-07 | 2017-10-12 | The George Washington University | Methods and compositions targeting retroviral latency |
AU2017251116A1 (en) * | 2016-04-15 | 2018-12-06 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
WO2017178586A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
US20190136230A1 (en) * | 2016-05-06 | 2019-05-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
US20200208111A1 (en) * | 2016-06-09 | 2020-07-02 | Branden S. Moriarity | Genome-edited nk cell and methods of making and using |
EP4353750A2 (en) | 2016-06-24 | 2024-04-17 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
KR20230095129A (ko) | 2016-08-03 | 2023-06-28 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
KR102546839B1 (ko) * | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
CA3038532A1 (en) | 2016-10-05 | 2018-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin compounds and methods of preparing the same |
ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
US20190233516A1 (en) * | 2016-10-10 | 2019-08-01 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
CN106544321B (zh) * | 2016-10-13 | 2019-01-29 | 北京艺妙神州医疗科技有限公司 | 通用型car-t细胞及其制备方法和用途 |
KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
WO2018080541A1 (en) * | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene |
WO2018085802A1 (en) * | 2016-11-07 | 2018-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selecting therapy for a cancer patient |
EP3321280B8 (en) * | 2016-11-10 | 2021-03-10 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases |
WO2018087276A1 (en) * | 2016-11-10 | 2018-05-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Or10h1 modulators and uses thereof |
AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
KR20190085528A (ko) | 2016-11-22 | 2019-07-18 | 싱가포르국립대학교 | T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단 |
JP2020504086A (ja) * | 2016-11-23 | 2020-02-06 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストン脱アセチル化酵素阻害剤とcd38阻害剤とを含む医薬組み合わせ物及びその使用方法 |
EP3454871B1 (en) * | 2016-12-09 | 2019-06-26 | Onkimmune Limited | Engineered natural killer cells and uses thereof |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
JP7303749B2 (ja) * | 2017-01-13 | 2023-07-05 | セルダラ メディカル、エルエルシー | Tim-1を標的とするキメラ抗原受容体 |
US10440535B2 (en) | 2017-01-25 | 2019-10-08 | The George Washington University | System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets |
CA3054304A1 (en) * | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
KR20190141655A (ko) * | 2017-02-22 | 2019-12-24 | 알레타 바이오쎄라퓨틱스, 인크. | 종양 형질도입용 조성물 및 방법 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
IL269458B2 (en) | 2017-03-23 | 2024-02-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
US11690873B2 (en) | 2017-03-31 | 2023-07-04 | Cellectis Sa | Universal chimeric antigen receptor T cells specific for CD22 |
US20210147798A1 (en) * | 2017-05-08 | 2021-05-20 | Toolgen Incorporated | Artificially Manipulated Immune Cell |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
KR20200005596A (ko) | 2017-05-12 | 2020-01-15 | 크리스퍼 테라퓨틱스 아게 | 세포를 엔지니어링하기 위한 물질 및 방법, 및 면역-종양학에서의 그의 용도 |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CN106978445A (zh) * | 2017-06-12 | 2017-07-25 | 内蒙古大学 | CRISPER‑Cas9系统介导的山羊EDAR基因敲除的方法 |
JP2020524512A (ja) * | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体(CARs)の組成物およびその使用方法 |
JP2020529834A (ja) | 2017-06-30 | 2020-10-15 | プレシジョン バイオサイエンシズ,インク. | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
CN107312800B (zh) * | 2017-08-01 | 2020-02-07 | 北京舜雷科技有限公司 | 能敲低内源性pd-1表达的cik及其制备方法与应用 |
CN107541526B (zh) * | 2017-08-23 | 2019-12-10 | 北京瑞健科技有限公司 | 能敲低内源性ctla4表达的cik及制备方法与应用 |
EP3676376A2 (en) | 2017-08-30 | 2020-07-08 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
JP2021501587A (ja) * | 2017-11-03 | 2021-01-21 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Cd38指向性キメラ抗原受容体構築物 |
GB201719169D0 (en) * | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
AU2018396083A1 (en) | 2017-12-29 | 2020-05-21 | Cellectis | Method for improving production of CAR T cells |
WO2019149743A1 (en) | 2018-01-30 | 2019-08-08 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
SG11202006883QA (en) | 2018-02-01 | 2020-08-28 | Pfizer | Chimeric antigen receptors targeting cd70 |
AU2019215075A1 (en) | 2018-02-01 | 2020-08-20 | Pfizer Inc. | Antibodies specific for CD70 and their uses |
EP3768328A4 (en) * | 2018-03-23 | 2021-12-22 | Refuge Biotechnologies, Inc. | GENE REGULATION THROUGH CONDITIONAL NUCLEAR LOCALIZATION OF GENE-MODULATING POLYPEPTIDES |
EP3775228A4 (en) * | 2018-03-29 | 2022-02-23 | Fate Therapeutics, Inc. | ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE |
MX2020010461A (es) * | 2018-04-05 | 2021-01-15 | Juno Therapeutics Inc | Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados. |
US11786554B2 (en) | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
EP3784690A4 (en) | 2018-04-27 | 2022-01-19 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | FOXP3 EXPRESSION IN EDITED CD34+ CELLS |
PE20210666A1 (es) * | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
WO2019222423A1 (en) * | 2018-05-15 | 2019-11-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tumor cell killers and vaccines |
WO2019222545A1 (en) | 2018-05-16 | 2019-11-21 | Synthego Corporation | Methods and systems for guide rna design and use |
CA3103610A1 (en) * | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
AU2019302603A1 (en) * | 2018-07-13 | 2021-01-14 | Nanjing Legend Biotech Co., Ltd. | Co-receptor systems for treating infectious diseases |
CN110819589B (zh) * | 2018-08-13 | 2022-10-11 | 上海科技大学 | 一种增强免疫效应细胞功能的方法 |
BR112021003670A2 (pt) | 2018-08-28 | 2021-05-18 | Vor Biopharma, Inc. | células-tronco hematopoéticas geneticamente modificadas e seus usos |
CA3114911A1 (en) * | 2018-10-04 | 2020-04-09 | Rutgers, The State University Of New Jersey | Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides |
JP2022513412A (ja) * | 2018-10-31 | 2022-02-07 | ヒューマニゲン インコーポレイティッド | 癌を治療するための物質及び方法 |
WO2020102721A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als) |
AU2019387377A1 (en) | 2018-11-30 | 2021-06-17 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD38 immunotherapy |
AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
WO2020191248A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Method and compositions for editing nucleotide sequences |
WO2020194245A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone |
US20200316197A1 (en) * | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
US20200308284A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone |
US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
CN113993999B (zh) | 2019-04-03 | 2022-11-22 | 精密生物科学公司 | 包含microRNA适应的shRNA(shRNAmiR)的遗传修饰的免疫细胞 |
SG11202112032WA (en) | 2019-04-30 | 2021-11-29 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
US20220193029A1 (en) * | 2019-05-21 | 2022-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin compounds for enhancement of immunotherapy |
CA3143248A1 (en) * | 2019-06-14 | 2020-12-17 | 2Seventy Bio, Inc. | Compositions and methods for treating cancer |
JP2022544580A (ja) * | 2019-08-16 | 2022-10-19 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 骨髄性悪性腫瘍を処置するためのキメラ抗原受容体 |
KR20220119362A (ko) * | 2019-09-18 | 2022-08-29 | 모멘타 파머슈티컬스 인코포레이티드 | CD38을 표적으로 하는 조작된 Fc-항원 결합 도메인 작제물과 관련된 조성물 및 방법 |
JP2023501506A (ja) * | 2019-11-13 | 2023-01-18 | 上海医薬集団股▲フン▼有限公司 | T細胞機能を改善するtmem59タンパク質二量体またはキメラ発現受容体 |
CN114901808A (zh) * | 2019-11-13 | 2022-08-12 | 克里斯珀医疗股份公司 | 生产car-t细胞的方法 |
WO2022250433A1 (ko) * | 2021-05-24 | 2022-12-01 | 주식회사 센트릭스바이오 | Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
BR112022013445A2 (pt) * | 2020-01-08 | 2022-09-13 | Univ Texas | Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos |
CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
JP2023519304A (ja) * | 2020-03-27 | 2023-05-10 | ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー | 多発性骨髄腫における免疫療法の標的およびその同定方法 |
CN115777017A (zh) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技(上海)有限公司 | 用于t细胞工程改造的组合物及方法 |
JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート,インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
JP2023530408A (ja) * | 2020-06-12 | 2023-07-18 | ンカルタ・インコーポレイテッド | Cd70指向性がん免疫療法のための遺伝子修飾されたナチュラルキラー細胞 |
CN111796101B (zh) * | 2020-07-14 | 2022-08-26 | 汕头市中心医院 | Notch3蛋白表达量检测剂联合cypa蛋白表达量检测剂在预测癌症治疗疗效的用途 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
JPWO2022210487A1 (es) * | 2021-03-29 | 2022-10-06 | ||
CA3216175A1 (en) * | 2021-04-05 | 2022-10-13 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
CN113671196B (zh) * | 2021-07-29 | 2023-09-12 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
WO2023088440A1 (en) * | 2021-11-18 | 2023-05-25 | Correctsequence Therapeutics | Regeneration of surface antigen-negative cells |
CN114350616A (zh) * | 2022-01-24 | 2022-04-15 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其制备方法和应用 |
WO2023147293A2 (en) * | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars) |
WO2023168087A1 (en) * | 2022-03-04 | 2023-09-07 | Yale University | Methods and compositions for treating and preventing fibrosis |
CN114397464B (zh) * | 2022-03-24 | 2022-06-10 | 天津德祥生物技术有限公司 | 一种红细胞膜碎片与载体的偶联复合物、其偶联方法和应用 |
WO2023194501A1 (en) * | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
CN114569709B (zh) * | 2022-05-05 | 2022-07-12 | 苏州慧疗生物医药科技有限公司 | 高表达adam-28的黑色素瘤自体肿瘤疫苗的制备方法及其应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
CN1826408B (zh) | 2003-03-14 | 2011-01-26 | 塞托·帕尔斯科技公司 | 大容量离体电穿孔法 |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
EP2325307A1 (en) | 2005-03-15 | 2011-05-25 | Cellectis | I-crel meganuclease variants with modified specificity, method of preparation and uses thereof |
AU2006272634B2 (en) * | 2005-07-26 | 2013-01-24 | Sangamo Therapeutics, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
JP5328018B2 (ja) | 2006-06-05 | 2013-10-30 | 国立大学法人広島大学 | 抗cd38抗体を細胞表面に有する免疫担当細胞 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP4186978A1 (en) * | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
US9617343B2 (en) * | 2009-05-13 | 2017-04-11 | Genzyme Corporation | Methods and compositions for treating lupus |
JP2013520999A (ja) * | 2010-03-04 | 2013-06-10 | ベット・セラピューティクス・インコーポレイテッド | Cd52に対するモノクローナル抗体 |
CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
NZ713462A (en) | 2010-10-27 | 2017-01-27 | Baylor College Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
AP2013006918A0 (en) * | 2010-12-09 | 2013-06-30 | Univ Pennsylvania | Use of chimeric antigen receptormodified T-cells to treat cancer |
CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
JP2014513948A (ja) | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β2ミクログロブリン欠損細胞 |
US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
WO2013176915A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
BR112015000638A2 (pt) | 2012-07-13 | 2017-08-08 | Univ Pennsylvania | sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor |
EP2877488B1 (en) | 2012-07-24 | 2021-02-24 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
WO2014039523A1 (en) | 2012-09-04 | 2014-03-13 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
WO2016187104A1 (en) * | 2015-05-15 | 2016-11-24 | Oru Kayak, Inc. | Collapsible kayak with large cockpit |
-
2015
- 2015-02-13 EP EP18194851.4A patent/EP3505623A1/en active Pending
- 2015-02-13 TR TR2018/19571T patent/TR201819571T4/tr unknown
- 2015-02-13 US US15/118,801 patent/US10836998B2/en active Active
- 2015-02-13 DK DK15706399.1T patent/DK3105317T3/en active
- 2015-02-13 PT PT15706399T patent/PT3105317T/pt unknown
- 2015-02-13 RU RU2016136702A patent/RU2714258C2/ru active
- 2015-02-13 HU HUE15706399A patent/HUE041497T2/hu unknown
- 2015-02-13 AU AU2015216875A patent/AU2015216875B2/en active Active
- 2015-02-13 MX MX2016010345A patent/MX2016010345A/es unknown
- 2015-02-13 BR BR112016017806-8A patent/BR112016017806B1/pt active IP Right Grant
- 2015-02-13 CN CN201580008739.XA patent/CN106029875A/zh active Pending
- 2015-02-13 WO PCT/EP2015/053162 patent/WO2015121454A1/en active Application Filing
- 2015-02-13 CA CA2937711A patent/CA2937711C/en active Active
- 2015-02-13 JP JP2016551704A patent/JP6673838B2/ja active Active
- 2015-02-13 ES ES15706399T patent/ES2711498T3/es active Active
- 2015-02-13 KR KR1020167025575A patent/KR102157924B1/ko active IP Right Grant
- 2015-02-13 EP EP15706399.1A patent/EP3105317B1/en active Active
- 2015-02-13 PL PL15706399T patent/PL3105317T3/pl unknown
-
2016
- 2016-07-07 IL IL246645A patent/IL246645B/en active IP Right Grant
- 2016-08-09 NO NO20161276A patent/NO20161276A1/en unknown
-
2020
- 2020-07-27 US US16/939,466 patent/US11692169B2/en active Active
-
2023
- 2023-05-22 US US18/321,481 patent/US20230357719A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TR201819571T4 (tr) | 2019-01-21 |
EP3505623A1 (en) | 2019-07-03 |
US20230357719A1 (en) | 2023-11-09 |
RU2714258C2 (ru) | 2020-02-13 |
CN106029875A (zh) | 2016-10-12 |
RU2016136702A (ru) | 2018-03-19 |
CA2937711A1 (en) | 2016-07-22 |
HUE041497T2 (hu) | 2019-05-28 |
BR112016017806A2 (pt) | 2017-10-10 |
WO2015121454A1 (en) | 2015-08-20 |
CA2937711C (en) | 2020-10-20 |
JP6673838B2 (ja) | 2020-04-01 |
ES2711498T3 (es) | 2019-05-06 |
IL246645B (en) | 2021-02-28 |
KR102157924B1 (ko) | 2020-10-26 |
US11692169B2 (en) | 2023-07-04 |
NO20161276A1 (en) | 2016-08-09 |
DK3105317T3 (en) | 2019-01-14 |
RU2016136702A3 (es) | 2018-08-17 |
KR20160138404A (ko) | 2016-12-05 |
US20200407682A1 (en) | 2020-12-31 |
PL3105317T3 (pl) | 2019-02-28 |
US20180201901A1 (en) | 2018-07-19 |
PT3105317T (pt) | 2019-02-27 |
IL246645A0 (en) | 2016-08-31 |
EP3105317A1 (en) | 2016-12-21 |
BR112016017806B1 (pt) | 2023-05-02 |
AU2015216875B2 (en) | 2021-02-25 |
AU2015216875A1 (en) | 2016-07-28 |
US10836998B2 (en) | 2020-11-17 |
EP3105317B1 (en) | 2018-09-19 |
JP2017506636A (ja) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016010345A (es) | Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas. | |
MX2018001776A (es) | Celulas para inmunoterapia modificadas geneticamente para dirigirse al antigeno cd38 y para la inactivacion del gen cd38. | |
AU2020201465A1 (en) | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing | |
PH12020551666A1 (en) | Vectors for expression of prostate-associated antigens | |
MA39819A (fr) | Méthodes et compositions d'immunomodulation | |
PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
MX2019007020A (es) | Anticuerpos il-11. | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
GB2557123A (en) | Modified cells and methods of therapy | |
MX2017007196A (es) | Fibroblastos de embrion de pollo inmortalizados. | |
SG10201810150UA (en) | Compositions and methods for enhanced gene expression in cone cells | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
MA40061A (fr) | Compositions immunogènes à base de listeria pour provoquer des réponses anti-tumorales | |
MX2016014235A (es) | Biosintesis microbiana de ergotioneina. | |
MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
MX2016015893A (es) | Produccion de fragmentos de fragmento cristalizable (fc). | |
MY197117A (en) | Compositions and methods for active surveillance of prostate cancer | |
CA2934815C (en) | Genetic markers associated with suicide risk and methods of use thereof | |
CL2019001002A1 (es) | Métodos y composiciones para inmunoterapia por tusc2. | |
MY184391A (en) | Microorganism having improved intracellular energy level and method for producing l-amino acid using same | |
MX2021009154A (es) | Selectividad eficaz de proteinas recombinantes. | |
MX2020005424A (es) | Composiciones y metodos para terapia contra el cancer. |